Michael J. Sofia - 01 Feb 2023 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role: Chief Scientific Officer
Signature: /s/ David C. Hastings as attorney-in-fact for Michael J. Sofia
Issuer symbol: ABUS
Transactions as of: 01 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2023, 15:11:39 UTC
Previous filing: 20 Jan 2022
Next filing: 05 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABUS	Common Shares	Award	$0	+82,200	+6.3%	$0.000000	1,385,603	01 Feb 2023	Direct	F1
holding	ABUS	Common Shares						167,162	01 Feb 2023	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+328,700		$0.000000	328,700	01 Feb 2023	Common Shares	328,700	$2.90	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2	These shares are owned by the Irrevocable Deed of Trust of Michael J. Sofia dated July 6, 2020 (the "Trust"). The Reporting Person's wife and adult children are both the Trustees and the beneficiaries of the Trust. The Reporting Person disclaims beneficial ownership of the shares owned by the Trust and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3	This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.